Comparison of R-CHOP-14 and R-mini-CHOP in older adults with diffuse large B-cell lymphoma-A retrospective multicenter cohort study.

Autor: Dilbaz ZG; Department of Oncology, Hematology, Rheumatology and Clinical Immunology, Saarland University Medical Center, Homburg, Germany.; Medical Faculty, Saarland University, Homburg, Germany., Denker S; Medical Department, Division of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany., Ankermann C; Medical Department, Division of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Bittenbring JT; Department of Oncology, Hematology, Rheumatology and Clinical Immunology, Saarland University Medical Center, Homburg, Germany.; Medical Faculty, Saarland University, Homburg, Germany., Kaddu-Mulindwa D; Department of Oncology, Hematology, Rheumatology and Clinical Immunology, Saarland University Medical Center, Homburg, Germany.; Medical Faculty, Saarland University, Homburg, Germany., Kunte AS; Department of Stem Cell Transplantation, Hamburg-Eppendorf University Medical Center, Hamburg, Germany., Hünecke S; Helios Universitätsklinikum Wuppertal, Wuppertal, Germany., Poeschel V; Department of Oncology, Hematology, Rheumatology and Clinical Immunology, Saarland University Medical Center, Homburg, Germany.; Medical Faculty, Saarland University, Homburg, Germany., Stilgenbauer S; Ulm Comprehensive Cancer Center, Ulm, Germany.; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany., Thurner L; Department of Oncology, Hematology, Rheumatology and Clinical Immunology, Saarland University Medical Center, Homburg, Germany.; Medical Faculty, Saarland University, Homburg, Germany., Na IK; Medical Department, Division of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; ECRC Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Partner site Berlin, Berlin, Germany., Bewarder M; Department of Oncology, Hematology, Rheumatology and Clinical Immunology, Saarland University Medical Center, Homburg, Germany.; Medical Faculty, Saarland University, Homburg, Germany., Christofyllakis K; Department of Oncology, Hematology, Rheumatology and Clinical Immunology, Saarland University Medical Center, Homburg, Germany.; Medical Faculty, Saarland University, Homburg, Germany.
Jazyk: angličtina
Zdroj: European journal of haematology [Eur J Haematol] 2024 Nov; Vol. 113 (5), pp. 675-684. Date of Electronic Publication: 2024 Jul 31.
DOI: 10.1111/ejh.14268
Abstrakt: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma entity, and its incidence increases with age. There is a paucity of data regarding use of biweekly R-CHOP (R-CHOP-14) in patients ≥80 years of age. We performed a retrospective cohort study of patients with DLBCL aged ≥80 years treated with R-CHOP-14 and R-miniCHOP in two academic tertiary centers in Germany between 01/01/2005 and 12/30/2019. Overall, 79 patients were included. Median age was 84 years (range 80-91). Despite higher CR rates with R-CHOP-14 (71.4% vs. 52.4%), no statistically significant difference could be found between patients treated with R-CHOP-14 and R-miniCHOP regarding overall survival (OS) (p = .88, HR 0.94, 95% CI = 0.47-1.90) and progression-free survival (PFS) (p = .26, HR 0.66, 95% CI = 0.32-1.36). At a median follow-up of 40 months, the 2-year OS rates were 56% with R-CHOP-14 and 53% with R-miniCHOP. Two-year PFS rates were 46% for R-CHOP-14 and 50% for R-mini-CHOP. Relative dose intensity of chemotherapy did not correlate with OS (p = .72). With the caveat of a retrospective cohort study, we conclude that lacking a difference in OS, R-miniCHOP should be preferred for most patients with untreated DLBCL aged ≥80 years.
(© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: